BRCA2 and neoplasm: Yet, PARG inhibition as a therapeutic strategy is directly questioned by reports, showing that PARG downregulation enables PARPi resistance in BRCA2 and p53-null mouse cell-line33, and that PARG deficiency had little impact on BRCA1- and/or PTEN-deficient tumor cells34.